公开(公告)号：US20200024319A1

公开(公告)日：2020-01-23

申请号：US15565376

申请日：2016-05-04

Applicant: AMGEN INC. ,  Amgen Inc.

Inventor： Eric Alan BUTZ ,  Christy Ann THOMSON ,  Marc Alain GAVIN ,  Ian Nevin FOLTZ ,  Dong XIA ,  Dina N. ALCORN ,  Ai Ching LIM ,  Randal Robert KETCHUM ,  Kathy MANCHULENKO ,  Laura SEKIROV ,  Kelly Ann BERRY ,  Cyr Clovis Chua DE IMUS ,  Neeraj Jagdish AGRAWAL ,  Gunasekaran KANNAN ,  Li LI

IPC: C07K14/55 ,  C07K16/24 ,  A61K38/20 ,  A61P37/00

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20170015750A1

公开(公告)日：2017-01-19

申请号：US15280662

申请日：2016-09-29

Applicant: AMGEN INC.

Inventor： Shaw-Fen Sylvia HU ,  Ian Nevin FOLTZ ,  Chadwick Terence KING ,  Yang LI ,  Taruna Arora

IPC: C07K16/28

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

Abstract translation: 本发明提供与抗原结合蛋白有关或衍生自抗原结合蛋白的组合物和方法激活FGF21介导的信号传导。 在实施方案中，抗原结合蛋白特异性结合（i）β-Klotho; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 在一些实施方案中，抗原结合蛋白诱导FGF21样信号传导。 在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，所述抗体的结合片段和衍生物，以及特异性结合（i）β-Klotho的多肽; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 其它实施方案提供了编码这种抗原结合蛋白的核酸及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物以及多肽，以及使用这些抗原结合蛋白的方法 ，其片段及其衍生物和多肽，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症的受试者的方法。

公开(公告)号：US20220281966A1

公开(公告)日：2022-09-08

申请号：US17630437

申请日：2020-07-24

Applicant: AMGEN INC.

Inventor： Agnieszka KIELCZEWSKA ,  Ian Nevin FOLTZ ,  Palaniswami RATHANASWAMI ,  Maria Sheena AMADOR ,  Bram ESTES ,  Igor D'ANGELO

IPC: C07K16/24 ,  A61P11/00 ,  A61P11/08 ,  A61P11/06 ,  A61P17/00

Abstract: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided.

公开(公告)号：US20210139554A1

公开(公告)日：2021-05-13

申请号：US17065395

申请日：2020-10-07

Applicant: Amgen Inc.

Inventor： Eric Alan BUTZ ,  Christy Ann THOMSON ,  Marc Alain GAVIN ,  Ian Nevin FOLTZ ,  Dong XIA ,  Dina N. ALCORN ,  Randal Robert KETCHEM ,  Ai Ching LIM ,  Kathy MANCHULENKO ,  Laura SEKIROV ,  Kelly Ann BERRY ,  Cyr Clovis Chua DE IMUS ,  Neeraj Jagdish AGRAWAL ,  Gunasekaran KANNAN ,  Li LI

IPC: C07K14/55 ,  A61P37/00 ,  A61K38/20 ,  C07K16/24

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20190248906A1

公开(公告)日：2019-08-15

申请号：US16282834

申请日：2019-02-22

Applicant: Amgen, Inc.

Inventor： Yang LI ,  Jennitte LeAnn STEVENS ,  Chadwick Terence KING ,  Ian Nevin FOLTZ ,  Gunasekaran KANNAN ,  Junming YIE ,  Shaw-Fen Sylvia HU

IPC: C07K16/28 ,  C07K14/71 ,  C07K16/40

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2319/00 ,  C07K2319/30 ,  C12Y302/01031

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

公开(公告)号：US20250066470A1

公开(公告)日：2025-02-27

申请号：US18435746

申请日：2024-02-07

Applicant: AMGEN INC.

Inventor： Sue J. SOHN ,  Marissa MOCK ,  Ian Nevin FOLTZ ,  Agnieszka KIELCZEWSKA ,  Kathy MANCHULENKO ,  Yannick BULLIARD ,  Xiaoshan MIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.

公开(公告)号：US20220017616A1

公开(公告)日：2022-01-20

申请号：US17375958

申请日：2021-07-14

Applicant: AMGEN INC.

Inventor： Sue J. SOHN ,  Marissa MOCK ,  Ian Nevin FOLTZ ,  Agnieszka KIELCZEWSKA ,  Kathy MANCHULENKO ,  Yannick BULLIARD ,  Xiaoshan MIN

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.

公开(公告)号：US20170183412A1

公开(公告)日：2017-06-29

申请号：US15400800

申请日：2017-01-06

Applicant: Amgen Inc.

Inventor： Yang LI ,  Jennitte LeAnn STEVENS ,  Chadwick Terence KING ,  Ian Nevin FOLTZ ,  Gunasekaran KANNAN ,  Junming YIE ,  Shaw-Fen Sylvia HU

IPC: C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2319/00 ,  C07K2319/30 ,  C12Y302/01031

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

公开(公告)号：US20240327486A1

公开(公告)日：2024-10-03

申请号：US18627761

申请日：2024-04-05

Applicant: Amgen Inc.

Inventor： Eric Alan BUTZ ,  Christy Ann THOMSON ,  Marc Alain GAVIN ,  Ian Nevin FOLTZ ,  Dong XIA ,  Dina N. ALCORN ,  Randal Robert KETCHEM ,  Ai Ching LIM ,  Kathy MANCHULENKO ,  Laura SEKIROV ,  Kelly Ann BERRY ,  Cyr Clovis Chua DE IMUS ,  Neeraj Jagdish AGRAWAL ,  Gunasekaran KANNAN ,  Li LI

IPC: C07K14/55 ,  A61K38/20 ,  A61P37/00 ,  C07K16/24

CPC classification number: C07K14/55 ,  A61K38/2013 ,  A61P37/00 ,  C07K16/246 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20220017636A1

公开(公告)日：2022-01-20

申请号：US17323884

申请日：2021-05-18

Applicant: Amgen Inc. ,  Amgen Research (Munich) GmbH ,  Immatics Biotechnologies GmbH

Inventor： Ian Nevin FOLTZ ,  Weihsu Claire CHEN ,  Lars GAEDTKE ,  Susmith MUKUND ,  Tobias RAUM ,  Heiko SCHUSTER ,  Kristin TARBELL ,  Derek E. PIPER ,  Johannes BROZY ,  Markus MUENZ ,  Igor D'ANGELO

IPC: C07K16/30 ,  C07K16/28 ,  A61P35/00

Abstract: The present invention relates to antibody constructs comprising a domain which binds to a MAGEB2 peptide complexed with an HLA and optionally, another domain which binds to CD3. Moreover, the invention provides polynucleotides encoding the antibody constructs, vectors comprising said polynucleotides and host cells transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the antibody constructs of the invention, medical uses of said antibody constructs, and kits comprising said antibody constructs.